Beth Hoffman
Company: Origami Therapeutics
Job title: Chief Executive Officer
Seminars:
Chair’s Closing Remarks 4:00 pm
day: Conference Day One
Chair’s Opening Remarks 8:55 am
day: Conference Day Two
Panel Discussion: Breaking Down the Pitfalls in Protein Degrader Assays & Brainstorming CNS-Specific Considerations 11:45 am
Streamlining PROTAC sample handling to foster standardized degrader assay development and analysis Evaluating PROTAC behavior as small molecules to understand mechanism of action Spotlighting additional PK and in vitro cost and time burdens in non-optimized assay conditionsRead more
day: Conference Day Two
Chair’s Closing Remarks 2:15 pm
day: Conference Day Two
Fireside Chat: Navigating the Future Development of Protein Degraders for CNS & Making the Most of Early Industry Collaboration 1:45 pm
To what extent are gaps in biological understanding hampering development of CNS protein degraders? What are the short to medium term barriers to overcome to accelerate CNS degrader development on par with oncology? How can the drug development community collaborate and mutually benefit in exploring TPD applications to CNS?Read more
day: Conference Day Two